Lessons from the SWITCH trial changing glucocorticoids in the management of metastatic castrationresistant prostate cancer mCRPC

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)

06:18 EDT 22 Oct 2018 | Nature Publishing

More From BioPortfolio on "Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)"